Managers

Kymera Therapeutics attracts $65 mln Series B

Cambridge, Massachusetts-based Kymera Therapeutics Inc, a biotechnology company, has closed $65 million in Series B financing. The lead investors were 6 Dimensions Capital, Bessemer Venture Partners and Pfizer Ventures.

Panache signs Telus as LP, increases Fund I target to $50 mln

Panache Ventures has signed up Telus Ventures, the strategic investment arm of Canadian telecommunications company Telus Corp, as a limited partner. Panache, a Canadian seed-stage venture capital firm, also announced it will extend fundraising for Panache Ventures I and increase its target to $50 million from $40 million. Fund I raised an initial $25 million earlier this year. To date, Montréal-based Panache has closed 28 investments in IT security, content marketing, business and productivity software, marketplace, financial technology, digital media, life sciences, logistics and supply chain management, health and fitness, and other sectors.

Ribometrix scores $30 mln Series A

Durham, North Carolina-based Ribometrix, a biotechnology company, has closed $30 million in Series A financing. M Ventures led the round with participation from Amgen Ventures, Pappas Capital and Illumina Ventures. Founding investors SV Health Investors, AbbVie Ventures, Hatteras Venture Partners, MP Healthcare Venture Management, the Dementia Discovery Fund and Alexandria Venture Investments.

Resolute Ventures to raise $75 mln venture-capital fund

Resolute Ventures has set out to raise a $75 million fourth venture-capital fund, according to a filing with the SEC.

Ex KP's Michael Linse to raise $65 mln venture fund

Linse Capital has set out to raise $65 million for a venture-capital fund, according to a filing with the SEC.

Fund Performance: SFERS venture portfolio (2002 to 2007)

AEGEA Medical fetches $17 mln

Menlo Park, California-based AEGEA Medical Inc, a medical device company, has raised $17 million in financing. Solas BioVentures led the round.

Harpoon Therapeutics snags $70 mln Series C

South San Francisco-based Harpoon Therapeutics Inc, a clinical-stage immunotherapy company, has raised $70 million in Series C financing. OrbiMed led the round with participation from other investors that included Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures, NS Investment, MPM Capital, Oncology Impact Fund, Arix Bioscience, New Leaf Venture Partners and Taiho Ventures LLC.

Teamworthy to raise $80 mln second venture-capital fund

Teamworthy Ventures has set out to raise an $80 million second venture-capital fund, according to a filing with the SEC.

M13 to raise $150 mln second venture-capital fund

M13 Ventures has set out to raise a $150 million second venture-capital fund, according to a filing with the SEC.